Tae-Min Kim

67PUBLICATIONS
372CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (67)

|Oct 26, 2026
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

|Oct 22, 2026
CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma.

|Oct 05, 2026
Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.

|Sep 17, 2026
Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.

|Aug 31, 2026
Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Pageof 12

Frequent Collaborators

10 joint publications

Chul-Kee Park

7 joint publications

Dong-Wan Kim

7 joint publications

Sung-Hye Park

6 joint publications

Byoung Chul Cho